Video

Debunking Clinical Trial Myths

Many patients with ovarian cancer have misconceptions about the care they will receive while on a clinical trial, according to Laurel W. Rice, M.D.

Clinical trials lead to new advancements in ovarian cancer, but many patients may be apprehensive to go on them. So, it is crucial that they understand what a trial is all about, according to Laurel W. Rice, M.D., chair of the Department of Obstetrics and Gynecology and a professor in the Division of Gynecologic Oncology at the University of Wisconsin-Madison School of Medicine and Public Health, and president of the Society for Gynecologic Oncology (SGO).

While some trials do include an arm of patients who receive a placebo, many more actually compare an investigative medicine versus a standard-of-care treatment, so all participants are getting treated. SGO was involved in developing an easy-to-understand video that helps patients better understand clinical trials.

Related Videos
Image of woman with blonde hair.
Image of woman with brown hair.
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Related Content